- Trial phase
- Approved
- Time to market
- Already marketed since 2014. The most recent label expansion (pediatric HABP/VABP) was approved in May 2026. Patent protection extends to approximately February 2036 per FDA-listed patents.
- Why 3/10
- ZERBAXA is an already-approved, marketed drug with no pending PDUFA date, Advisory Committee, or pivotal readout in the next ~12 months. The most recent catalyst (pediatric label expansion) was completed in May 2026. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5, and ZERBAXA's small contribution to Merck's $65B+ revenue base anchors it at the low end of that range.
ZERBAXA has no upcoming PDUFA dates or pivotal readouts in the next 12 months. Investors should watch quarterly Merck earnings reports for ZERBAXA sales trends, particularly whether the May 2026 pediatric label expansion drives measurable revenue acceleration. The key competitive dynamic to monitor is how ZERBAXA fares against Avycaz and Vabomere in the hospital antibiotic market, especially for Pseudomonas coverage. For MRK investors, ZERBAXA is a minor product; the stock's primary drivers remain Keytruda, Gardasil, and the broader pipeline.
Price Chart
Executive Summary
ZERBAXA (ceftolozane/tazobactam) is a hospital-use IV antibiotic from Merck & Co., Inc. (NYSE: MRK) that targets multidrug-resistant gram-negative infections, including Pseudomonas aeruginosa. First approved by the FDA in December 2014 for complicated intra-abdominal and urinary tract infections, it later added hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in adults. The FDA approved a pediatric label expansion in May 2026. With estimated 2024 sales of roughly $252M, ZERBAXA is a small but growing product within Merck's massive $65B+ pharmaceutical portfolio. Patent protection runs to approximately February 2036. No upcoming binary catalysts are scheduled, making this a steady commercial-stage asset rather than a near-term stock-moving event.
How It Works
ZERBAXA is a combination of two drugs in one IV infusion: ceftolozane (a cephalosporin antibiotic that kills certain gram-negative bacteria by disrupting their cell walls) and tazobactam (a beta-lactamase inhibitor that prevents bacteria from destroying ceftolozane). It is designed to treat multidrug-resistant infections, especially tough Pseudomonas aeruginosa and other hard-to-kill gram-negative bacteria in hospitalized patients.
Trial Status
ZERBAXA was initially FDA-approved in December 2014 for complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A pivotal Phase 3 trial (Trial 3) comparing ZERBAXA 3g every 8 hours against meropenem in 720 patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) met its primary non-inferiority endpoint, leading to FDA approval for that indication in adults. In May 2026, the FDA expanded the label to include pediatric patients (at least 32 weeks gestational age) for HABP/VABP and broadened the pediatric age range for cIAI and cUTI based on an open-label PK/safety study (NCT04223752).
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates or pivotal readouts identified for ZERBAXA in the next 12 months. The drug is already approved for its core indications and the most recent label expansion (pediatric) was completed in May 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report